Madrigal Pharmaceuticals Secures $4.4B Deal for Six Preclinical siRNA Programs Targeting MASH from Ribo Life Science on February 12, 2026 Madrigal MASH Rezdiffra Ribo RNA, Small Interfering +
Madrigal Pharmaceuticals Inks up to $2B Deal with CSPC for Preclinical Oral GLP-1, Plans Combination with Rezdiffra for MASH on July 30, 2025 global license agreement GZMH gene Madrigal Pharmaceuticals MASH oral small molecule Pharmaceutical Group preclinical drug Product containing glucagon-like peptide 1 receptor agonist (product) Rezdiffra +